-
Biochemistry Feb 1977The three-dimensional crystal structure of bovine trypsinogen at approximately pH 7.5 was initially solved at 2.6 A resolution using the multiple isomorphous replacement...
The three-dimensional crystal structure of bovine trypsinogen at approximately pH 7.5 was initially solved at 2.6 A resolution using the multiple isomorphous replacement method. Preliminary refinement cycles of the atomic coordinates trypsinogen have been carried out first to a resolution of 2.1 A, and later to 1.9 A, using constrained difference Fourier refinement; During the process, structure factors Fc and phi c were calculated from the trypsinogen structure and final interpretation was based on an electron-density map computed with terms (2 Fo - Fc) and phases phic at a resolution of 1.9 A. Crystals of trypsinogen grown from ethanol-water mixtures are trigonal with space group P3121, and cell dimension a = 55.17 A and c = 109.25 A. The structure is compared with the bovine diisopropylphosphoryltrypsin structure at approximately pH 7.2, oirginally determined from orthohombic crystals by Stroud et al. (Stroud, R.M., Kay L.M., and Dickerson, R.E. (1971), Cold Spring Harbor Symp. Quant. Biol. 36, 125-140; Stroud, R.M., Kay, L.M., and Dickerson, R.E. (1974), J. Mol. Biol. 83, 185-208), and later refined at 1.5 A resolution by Chambers and Stroud (Chambers, J.L., and Stroud, R.M. (1976), Acta Crystallogr. (in press)). At lower pH, 4.0-5.5 diogen, with cell dimensions a = 55.05 A and c = 109.45 A. This finding was used in the solution of the six trypsinogen heavy-atom derivatives prior to isomorphous phase analysis, and as a further basis of comparison between trypsinogen and the low pH trypsin structure. There are small differences between the two diisopropylphosphoryltrypsin structures. Bovine trypsinogen has a large and accessible cavity at the site where the native enzyme binds specific side chains of a substrate. The conformation and stability of the binding site differ from that found in trypsin at approximately pH 7.5, and from that in the low pH form of diisopropylphosphoryltrypsin. The catalytic site containing Asp-102, His-57, and Ser-195 is similar to that found in trypsin and contains a similar hydrogen-bounded network. The carboxyl group of Asp-194, which is salt bridged to the amino terminal of Ile-16 in native trypsin or other serine proteases, is apparently hydrogen bonded to internal solvent molecules in a loosely organized part of the zymogen structure. The unusually charged N-terminal hexapeptide of trypsinogen, whose removal leads to activation of the zymogen, lies on the outside surface of the molecule. There are significant structural changes which accompany activation in neighboring regions, which include residues 142-152, 215-550, 188A-195. The NH group of Gly-193, normally involved in stabilization of reaction intermediates (Steitz, T.A., Henderson, R., and Blow, D.M. (1969), J. Mol. Biol. 46, 337-348; Henderson, R. (1970), J. Mol. Biol. 54, 341-354; robertus, J.D., Kraut, J., Alden, R.A., and Birkoft, J.J. (1972), Biochemistry 11, 4293-4303) in the enzyme, is moved 1.9 A away from its position in trypsin...
Topics: Animals; Binding Sites; Cattle; Fourier Analysis; Macromolecular Substances; Mathematics; Models, Molecular; Protein Binding; Protein Conformation; Trypsin; Trypsinogen; X-Ray Diffraction
PubMed: 556951
DOI: 10.1021/bi00623a016 -
BMJ (Clinical Research Ed.) Jul 1991
Topics: Humans; Infant, Newborn; Intestinal Obstruction; Meconium; Trypsinogen
PubMed: 1859967
DOI: 10.1136/bmj.303.6793.56-a -
Ostrich trypsinogen: purification, kinetic properties and characterization of the pancreatic enzyme.The International Journal of... Jul 1995Trypsinogen is a serine protease zymogen (EC.3.4.21.4) which has proved to be of key significance in a family of about 20 structurally and functionally related...
Trypsinogen is a serine protease zymogen (EC.3.4.21.4) which has proved to be of key significance in a family of about 20 structurally and functionally related pancreatic digestive enzymes. This study was an endeavour to isolate, purify and characterize a stable form of ostrich trypsinogen, which has thus far not yet been accomplished. Trypsinogen (anionic) was isolated and purified by alkaline extraction of pancreatic acetone powder, followed by Toyopearl DEAE 650M, hydroxylapatite and LBTI-Sepharose affinity chromatography. The enzyme was chemically physically and kinetically characterized, using amidase and esterase activity and spectrofluorometric determinations. Effects of CaCl2 and pH, among others, were examined. Purification of homogeneous anionic ostrich trypsinogen was achieved. Immunochemical analysis and spectrofluorometric reaction with sulphonyl-Ala-Ala-Pro-Arg-7-amino-4-methylcoumarin indicated trypsin-free ostrich trypsinogen, with an average Mr of 23,016 and a pI of 4.93. N-terminal sequence data revealed an unique activation peptide sequence, VPGDADDDK. Certain concentrations of Ca2+ enhanced trypsinogen activation, whilst others appeared to have the opposite effect. The kcat/Km values obtained at different pHs, using N alpha-benzoyl-DL-arginine-p-nitroanilide, p-toluenesulphonyl-arginine-methylester and p-toluenesulphonyl-lysine-methylester, followed the pH profile activity trend closely, with maximum catalytic activity at about pH 8 for both ostrich and bovine activated trypsinogen. Ostrich trypsin has significantly higher amidase activity than bovine trypsin, while esterase activities of the two enzymes have an inverse ratio. Kinetic pKa values were 7.2 and 7.4 for ostrich and bovine activated trypsinogens, respectively. The existence of ostrich trypsinogen in a now homogeneous stable form, free of autocatalytic inducing impurities, together with its characterization scenario will hopefully make a significant contribution to the field of comparative biochemistry. This study also confirms that ostrich trypsinogen is closely related to its serine protease counterparts.
Topics: Amino Acid Sequence; Amino Acids; Animals; Birds; Calcium; Chromatography; Enteropeptidase; Enzyme Activation; Enzyme Stability; Kinetics; Molecular Sequence Data; Pancreas; Sequence Analysis; Sequence Homology, Amino Acid; Substrate Specificity; Trypsin; Trypsinogen
PubMed: 7648428
DOI: 10.1016/1357-2725(95)00033-l -
The American Journal of Pathology Dec 2000Trypsinogen is a serine proteinase produced mainly by the pancreas, but it has recently been found to be expressed also in several cancers such as ovarian and colon...
Trypsinogen is a serine proteinase produced mainly by the pancreas, but it has recently been found to be expressed also in several cancers such as ovarian and colon cancer and in vascular endothelial cells. In this study, we found that trypsinogen-1 and -2 are present at high concentrations (median levels, 0.4 and 0.5 mg/L, respectively) in human seminal fluid and purified them to homogeneity by immunoaffinity and anion exchange chromatography. Purified trypsinogen isoenzymes displayed a M(r) of 25 to 28 kd in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. Most of the trypsinogen-1 purified from seminal fluid was enzymatically active whereas trypsinogen-2 occurred as the proform, which could be activated by enteropeptidase in vitro. Immunohistochemically, trypsinogen protein was detected in the human prostate, urethra, utriculus, ejaculatory duct, seminal vesicles, deferent duct, epididymal glands, and testis. Expression of trypsinogen mRNA in the same organs was demonstrated by in situ hybridization. Trypsinogen mRNA was also detected in the prostate and seminal vesicles by reverse transcriptase-polymerase chain reaction and Northern blotting. Isolated trypsin was shown to activate the proenzyme form of prostate-specific antigen. These results suggest that trypsinogen isoenzymes found in seminal fluid are produced locally in the male genital tract and that they may play a physiological role in the semen.
Topics: Blotting, Northern; Genitalia, Male; Humans; Immunohistochemistry; In Situ Hybridization; Isoenzymes; Male; Prostate-Specific Antigen; Semen; Trypsin; Trypsinogen; Zinc
PubMed: 11106574
DOI: 10.1016/S0002-9440(10)64840-7 -
Biochemistry Feb 1972
Topics: Amino Acid Sequence; Amino Acids; Animals; Biological Evolution; Calcium Chloride; Chromatography, DEAE-Cellulose; Chromatography, Gel; Detergents; Electrophoresis, Disc; Electrophoresis, Paper; Enzyme Activation; Fishes; Kinetics; Pancreas; Peptides; Sulfuric Acids; Trypsinogen; Ultracentrifugation; Urea
PubMed: 5011961
DOI: 10.1021/bi00754a004 -
Biochemistry Aug 1987The trypsinogen to trypsin transition has been investigated by a stochastic boundary molecular dynamics simulation that included a major portion of the trypsin molecule...
The trypsinogen to trypsin transition has been investigated by a stochastic boundary molecular dynamics simulation that included a major portion of the trypsin molecule and the surrounding solvent. Attention focused on the "activation domain", which crystallographic studies have shown to be ordered in trypsin and disordered in its zymogen, trypsinogen. The chain segments that form the activation domain were found to exhibit large fluctuations during the simulation of trypsin. To model a difference between trypsin and trypsinogen, the N-terminal residues Ile-16 and Val-17 were removed in the former and replaced by water molecules. As a result of the perturbation, a structural drift of 1-2 A occurred that is limited to the activation domain. Glycine residues are found to act as hinges for the displaced chain segments.
Topics: Amino Acid Sequence; Enzyme Activation; Kinetics; Models, Molecular; Protein Conformation; Trypsin; Trypsinogen
PubMed: 3663651
DOI: 10.1021/bi00390a039 -
The Journal of Biological Chemistry Jun 2016The human pancreas expresses two major trypsinogen isoforms, cationic trypsinogen (PRSS1) and anionic trypsinogen (PRSS2). Mutations in PRSS1 cause hereditary...
The human pancreas expresses two major trypsinogen isoforms, cationic trypsinogen (PRSS1) and anionic trypsinogen (PRSS2). Mutations in PRSS1 cause hereditary pancreatitis by altering cleavage of regulatory nick sites by chymotrypsin C (CTRC) resulting in reduced trypsinogen degradation and increased autoactivation. Despite 90% identity with PRSS1 and a strong propensity for autoactivation, mutations in PRSS2 are not found in hereditary pancreatitis suggesting that activation of this isoform is more tightly regulated. Here, we demonstrated that CTRC promoted degradation and thereby markedly suppressed autoactivation of human anionic trypsinogen more effectively than previously observed with cationic trypsinogen. Increased sensitivity of anionic trypsinogen to CTRC-mediated degradation was due to an additional cleavage site at Leu-148 in the autolysis loop and the lack of the conserved Cys-139-Cys-206 disulfide bond. Significant stabilization of anionic trypsinogen against degradation was achieved by simultaneous mutations of CTRC cleavage sites Leu-81 and Leu-148, autolytic cleavage site Arg-122, and restoration of the missing disulfide bridge. This stands in stark contrast to cationic trypsinogen where single mutations of either Leu-81 or Arg-122 resulted in almost complete resistance to CTRC-mediated degradation. Finally, processing of the trypsinogen activation peptide at Phe-18 by CTRC inhibited autoactivation of anionic trypsinogen, although cationic trypsinogen was strongly stimulated. Taken together, the observations indicate that human anionic trypsinogen is controlled by CTRC in a manner that individual natural mutations are unlikely to increase stability enough to promote intra-pancreatic activation. This unique biochemical property of anionic trypsinogen explains the lack of association of PRSS2 mutations with hereditary pancreatitis.
Topics: Chymotrypsin; Cystine; Enzyme Activation; Enzyme Stability; Humans; Mutation, Missense; Pancreatitis; Protein Processing, Post-Translational; Proteolysis; Trypsin; Trypsinogen
PubMed: 27129265
DOI: 10.1074/jbc.M116.725374 -
Gastroenterology Mar 1999
Topics: Acute Disease; Animals; Ceruletide; Disease Models, Animal; Enzyme Activation; Oligopeptides; Pancreatitis; Rats; Trypsinogen
PubMed: 10094605
DOI: No ID Found -
International Journal of Cancer May 2000Many types of human tumor express trypsinogen-2, which may be a significant factor in the activation of pro-MMPs and the invasiveness of tumors. Prevention of...
Many types of human tumor express trypsinogen-2, which may be a significant factor in the activation of pro-MMPs and the invasiveness of tumors. Prevention of trypsinogen-2 expression in cancer cells might be of benefit in cancer therapy. We describe here chemicals capable of down-regulating the expression of trypsinogen-2. Doxycycline (DOXY) and chemically modified tetracyclines (CMTs), previously known as inhibitors of the matrix metalloproteinase (MMP)-dependent proteinase cascade, down-regulated the mRNA and protein expression of trypsinogen-2 by COLO-205 human colon adenocarcinoma cells at therapeutically attainable concentrations (0. 1 to 1.0 microM). DOXY specifically inhibited the activation of pro-MMP-9 and cell migration induced by enteropeptidase, a specific activator of trypsinogen. Pro-MMP-9 activation and cell migration were also inhibited by tumor-associated trypsin inhibitor (TATI), which is a highly specific inhibitor of trypsin. CMT-3 as well as CMT-5 also inhibited cell migration, but an effect on the enteropeptidase-enhanced activation of pro-MMP-9 was not observed. Our results indicate that CMTs, DOXY and TATI inhibit cancer cell migration by down-regulating trypsinogen-2 expression or activity. Inhibition of trypsinogen-2 expression may represent a mechanism contributing to the ability of CMTs to suppress the pericellular proteolytic activity of some tumors.
Topics: Antineoplastic Agents; Cell Division; Cell Movement; Down-Regulation; Enzyme Precursors; Gene Expression Regulation; Humans; Matrix Metalloproteinase 9; Tetracyclines; Trypsin; Trypsin Inhibitors; Trypsinogen; Tumor Cells, Cultured
PubMed: 10797274
DOI: 10.1002/(sici)1097-0215(20000515)86:4<577::aid-ijc21>3.0.co;2-j -
Molecular Genetics and Metabolism May 2012On May 23-24, 2011, a workshop entitled "Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: Technical Issues and Challenges" was held in Annapolis,...
On May 23-24, 2011, a workshop entitled "Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: Technical Issues and Challenges" was held in Annapolis, Maryland. The two-day workshop was co-hosted by the National Newborn Screening and Genetics Resource Center, Austin, Texas, and the Association of Public Health Laboratories, Silver Spring, Maryland, in collaboration with the Health Resources and Services Administration and the Centers for Disease Control and Prevention. Participants included nearly 40 representatives from U.S. state public health and commercial laboratories performing newborn dried blood spot screening tests for cystic fibrosis (CF), the federal government, academic research institutions, and commercial vendors of products used in newborn screening. Representatives from selected European CF newborn screening programs were also present. The workshop focused on identifying key IRT testing issues and mechanisms for achieving their resolution and laboratory harmonization in order to reduce, or eliminate completely, the late identified CF cases following a negative newborn screen. Informative findings are reported, their impacts on improving IRT screening are described, and their implications are discussed.
Topics: Biomarkers; Cystic Fibrosis; Dried Blood Spot Testing; Genetic Testing; Humans; Trypsinogen
PubMed: 22425451
DOI: 10.1016/j.ymgme.2012.02.013